AMRX insider transaction filings
Amneal Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen AMRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Kiely John — Director | Sale (S): 50,000 @ $17.64 · Gift (G): 10,000 @ $0 | EDGAR |
| 2026-08-13 | 4 | Daly Jason B. — EVP, Chief Legal Officer | Sale (S): 6,613 @ $17.70 · Sale (S): 210,000 @ $17.40 | EDGAR |
| 2026-08-13 | 4 | Shah Nikita — Executive Vice President | Sale (S): 146,403 @ $17.51 | EDGAR |
| 2026-08-13 | 4 | BUCHI J KEVIN — Director | Option exercise (M): 168,573 @ $17.18 | EDGAR |
| 2026-08-12 | 4 | Patel Tushar Bhikhubhai — 10% owner | Grant/award (A): 12,763,469 | EDGAR |
| 2026-08-12 | 4 | Patel Chintu — Co-CEO, Director | Grant/award (A): 6,381,734 | EDGAR |
| 2026-08-12 | 4 | Patel Gautam — Director | Grant/award (A): 283,632 | EDGAR |
| 2026-08-12 | 4 | Patel Chirag K. — President & Co-CEO, Director | Grant/award (A): 6,381,734 | EDGAR |
| 2026-05-12 | 4 | Autor Deborah M. — Director | Sale (S): 34,819 @ $12.94 | EDGAR |
| 2026-05-08 | 4 | Autor Deborah M. — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | George Jeffrey P. — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Patel Gautam — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Kiely John — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Yanai Shlomo — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Nark Ted C — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | BUCHI J KEVIN — Director | Option exercise (M): 34,819 · Option exercise (M): 34,819 (derivative) @ $0 · Grant/award (A): 19,824 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | MEISTER PAUL M — Director | Option exercise (M): 48,747 · Option exercise (M): 48,747 (derivative) @ $0 · Grant/award (A): 30,837 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4/A | Patel Chintu — Co-CEO, Director | Grant/award (A): 544,663 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4/A | Patel Chirag K. — President & Co-CEO, Director | Grant/award (A): 544,663 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Patel Chintu — Co-CEO, Director | Option exercise (M): 59,931 · Tax withholding (F): 17,112 @ $13.31 · Option exercise (M): 733,944 · Tax withholding (F): 315,885 @ $13.31 · Option exercise (M): 92,593 · Tax withholding (F): 28,983 @ $13.30 · +3 more | EDGAR |
| 2026-03-05 | 4 | Patel Chirag K. — President & Co-CEO, Director | Option exercise (M): 59,931 · Tax withholding (F): 15,616 @ $13.31 · Option exercise (M): 733,944 · Tax withholding (F): 297,537 @ $13.31 · Option exercise (M): 92,593 · Tax withholding (F): 37,825 @ $13.30 · +3 more | EDGAR |
| 2026-03-05 | 4 | Daly Jason B. — EVP, Chief Legal Officer | Option exercise (M): 22,645 · Tax withholding (F): 10,147 @ $13.31 · Option exercise (M): 38,226 · Tax withholding (F): 16,598 @ $13.31 · Option exercise (M): 24,258 · Tax withholding (F): 10,533 @ $13.31 · +9 more | EDGAR |
| 2026-03-05 | 4 | Shah Nikita — Executive Vice President | Option exercise (M): 36,232 · Tax withholding (F): 18,502 @ $13.31 · Option exercise (M): 45,871 · Tax withholding (F): 22,982 @ $13.31 · Option exercise (M): 23,544 · Tax withholding (F): 11,796 @ $13.31 · +9 more | EDGAR |
| 2026-03-05 | 4 | Konidaris Tasos — Executive Vice President & CFO | Option exercise (M): 45,290 · Tax withholding (F): 16,182 @ $13.31 · Option exercise (M): 57,339 · Tax withholding (F): 24,251 @ $13.31 · Option exercise (M): 28,538 · Tax withholding (F): 14,298 @ $13.31 · +9 more | EDGAR |
| 2026-03-05 | 4 | BOYER ANDREW S — Executive Vice President | Option exercise (M): 39,252 · Tax withholding (F): 19,945 @ $13.31 · Option exercise (M): 49,694 · Tax withholding (F): 24,897 @ $13.31 · Option exercise (M): 24,258 · Tax withholding (F): 12,154 @ $13.31 · +9 more | EDGAR |
| 2026-03-03 | 4 | Patel Chintu — Co-CEO, Director | Grant/award (A): 190,632 (derivative) @ $0 · Grant/award (A): 354,031 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Patel Chirag K. — President & Co-CEO, Director | Grant/award (A): 190,632 (derivative) @ $0 · Grant/award (A): 354,031 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Shah Nikita — Executive Vice President | Grant/award (A): 65,359 (derivative) @ $0 · Grant/award (A): 65,359 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Daly Jason B. — EVP, Chief Legal Officer | Grant/award (A): 65,359 (derivative) @ $0 · Grant/award (A): 65,359 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Konidaris Tasos — Executive Vice President & CFO | Grant/award (A): 72,622 (derivative) @ $0 · Grant/award (A): 72,622 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | BOYER ANDREW S — Executive Vice President | Grant/award (A): 65,359 (derivative) @ $0 · Grant/award (A): 65,359 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Nark Ted C — Director | Sale (S): 50,000 @ $11.72 | EDGAR |
| 2025-11-14 | 4 | Shah Nikita — Executive Vice President | Option exercise (M): 36,331 @ $2.75 · Option exercise (M): 95,525 @ $2.75 · Sale (S): 131,856 @ $11.92 · Option exercise (M): 36,331 (derivative) @ $0 · Option exercise (M): 95,525 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Kiely John — Director | Sale (S): 32,000 @ $9.23 | EDGAR |
| 2025-08-25 | 4 | Shah Nikita — Executive Vice President | Sale (S): 114,492 @ $9.66 · Sale (S): 6,340 @ $9.50 | EDGAR |
| 2025-08-22 | 4 | BOYER ANDREW S — Executive Vice President | Option exercise (M): 175,000 @ $2.75 · Sale (S): 279,244 @ $9.38 · Option exercise (M): 175,000 (derivative) @ $0 | EDGAR |
| 2025-08-15 | 4 | Shah Nikita — Executive Vice President | Sale (S): 71,694 @ $9.29 | EDGAR |
| 2025-08-15 | 4 | Konidaris Tasos — Executive Vice President & CFO | Sale (S): 161,365 @ $9.22 · Sale (S): 119,206 @ $9.30 · Sale (S): 219,159 @ $9.43 | EDGAR |
| 2025-08-13 | 4 | Shah Nikita — Executive Vice President | Sale (S): 50,000 @ $9.04 | EDGAR |
| 2025-08-13 | 4 | Daly Jason B. — EVP, Chief Legal Officer | Sale (S): 22,000 @ $9.05 | EDGAR |
| 2025-08-13 | 4 | BOYER ANDREW S — Executive Vice President | Sale (S): 33,436 @ $9.05 | EDGAR |
| 2025-06-18 | 4 | Patel Gautam — Director | Sale (S): 94,906 @ $8.02 | EDGAR |
| 2025-06-12 | 4 | Patel Gautam — Director | Sale (S): 56,426 @ $8.02 | EDGAR |
| 2025-05-19 | 4 | Shah Nikita — Executive Vice President | Sale (S): 49,140 @ $7.58 | EDGAR |
| 2025-05-13 | 4 | Kiely John — Director | Sale (S): 50,000 @ $7.59 | EDGAR |
| 2025-05-08 | 4 | Autor Deborah M. — Director | Option exercise (M): 40,258 · Option exercise (M): 40,258 (derivative) @ $0 · Grant/award (A): 34,819 (derivative) @ $0 | EDGAR |
| 2025-05-08 | 4 | Kiely John — Director | Option exercise (M): 40,258 · Option exercise (M): 40,258 (derivative) @ $0 · Grant/award (A): 34,819 (derivative) @ $0 | EDGAR |
| 2025-05-08 | 4 | George Jeffrey P. — Director | Option exercise (M): 40,258 · Option exercise (M): 40,258 (derivative) @ $0 · Grant/award (A): 34,819 (derivative) @ $0 | EDGAR |
| 2025-05-08 | 4 | Alva Emily Peterson — Director | Option exercise (M): 40,258 · Option exercise (M): 40,258 (derivative) @ $0 · Grant/award (A): 34,819 (derivative) @ $0 | EDGAR |
| 2025-05-08 | 4 | Patel Gautam — Director | Option exercise (M): 40,258 · Option exercise (M): 40,258 (derivative) @ $0 · Grant/award (A): 34,819 (derivative) @ $0 | EDGAR |
Recent 8-K events — Amneal Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-07-31 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-01-28 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AMRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →